HEALTH● LOW1h ago · Oct 22, 2026, 1:27 PM
Biohaven surges as FDA accepts resubmission for Vyglxia for spinocerebellar ataxia
Seeking Alpha Tech · north america
Biohaven's stock has surged after the FDA accepted its resubmission for Vyglxia, a drug for spinocerebellar ataxia. This indicates positive progress in the drug's regulatory approval process.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH20m agoAbbVie sees positive late-stage results for lutikizumab in hidradenitis suppurativaSeeking Alpha TechHEALTH28m agoThousands of cans of Walmart-brand fruit cocktail recalledThe HillHEALTH49m agoMedicaid billing abuse deprives autistic kids of therapy and taxpayers of trustThe HillHEALTH1h agoEbola: South-East governments step up containment measuresVanguard Nigeria